Mutations and loss of heterozygosity (LOH) in the IFN-γ signaling pathways in tumor cells quench an important immune-cell-mediated tumor cell death mechanism, thus potentially accelerating acquired resistance to ICBT. Here, IFNG is linked to neoplasm.